Drug Trial Radar · NCT04562870
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Last checked: Nov 21, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Mar 17, 2021
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.
Conditions
- Myelofibrosis
Interventions
SelinexorDrug
Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
Physician's Choice TreatmentOther
Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35)Time frame: From Baseline up to Week 24
Locations
21 sites in 7 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope and Innovation
Pasadena, California
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado
Illinois Cancer Specialist
Niles, Illinois
Texas Oncology - Northeast Texas
Tyler, Texas
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Suzhou University -The First Affiliated Hospital
Suzhou, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Centre Hospitalier Universitaire d'Angers (CHU Angers)
Angers, France
Institut de Cancéro-Hématologie
Brest, Brittany Region, France
University General Hospital "ATTIKON"
Athens, Attica, Greece
Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica
Florence, Italy
Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti
Latina, Italy
University of Perugia Department of Medicine Hematology Section
Perugia, Italy
Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi
Varese, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Meldola, Forlì-Cesena, Italy
Pratia Onkologia Katowice
Katowice, Poland
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.